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Abstract
Background: Multiple myeloma (MM) is an incurable haematological malignancy characterised by the clonal
proliferation of malignant plasma cells within the bone marrow. We have previously identified pituitary tumour
transforming gene 1 (Pttg1) as a gene that is significantly upregulated in the haematopoietic compartment of
the myeloma-susceptible C57BL/KaLwRij mouse strain, when compared with the myeloma-resistant C57BL/6
mouse. Over-expression of PTTG1 has previously been associated with malignant progression and an enhanced
proliferative capacity in solid tumours.
Methods: In this study, we investigated PTTG1 gene and protein expression in MM plasma cells from newly
diagnosed MM patients. Gene expression profiling was used to identify gene signatures associated with high
PTTG1 expression in MM patients. Additionally, we investigated the effect of short hairpin ribonucleic acid
(shRNA)-mediated PTTG1 knockdown on the proliferation of the murine myeloma plasma cell line 5TGM1 in vitro
and in vivo.
Results: PTTG1 was found to be over-expressed in 36–70 % of MM patients, relative to normal controls, with
high PTTG1 expression being associated with poor patient outcomes (hazard ratio 2.49; 95 % CI 1.28 to 4.86;
p = 0.0075; log-rank test). In addition, patients with high PTTG1 expression exhibited increased expression of cell
proliferation-associated genes including CCNB1, CCNB2, CDK1, AURKA, BIRC5 and DEPDC1. Knockdown of Pttg1 in
5TGM1 cells decreased cellular proliferation, without affecting cell cycle distribution or viability, and decreased
expression of Ccnb1, Birc5 and Depdc1 in vitro. Notably, Pttg1 knockdown significantly reduced MM tumour
development in vivo, with an 83.2 % reduction in tumour burden at 4 weeks (p < 0.0001, two-way ANOVA).
Conclusions: This study supports a role for increased PTTG1 expression in augmenting tumour development in
a subset of MM patients.
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Background
Multiple myeloma (MM) is characterised by the clonal
proliferation of malignant plasma cells within the bone
marrow (BM) and is the second most common haemato-
logical malignancy. The key clinical manifestations of
MM include the development of painful osteolytic bone
lesions, renal insufficiency, suppressed haematopoietic
function and increased BM angiogenesis [1]. There are
an array of clinical variants of the disease, ranging from
the asymptomatic monoclonal gammopathy of undeter-
mined significance (MGUS) and smouldering MM, to
the more aggressive active MM and plasma cell leukae-
mia. Numerous genes, pathways and miRNAs have been
identified in MM that function as predictive biomarkers
of highly proliferative disease and likelihood of response to
treatment [2–6]. Although the introduction of novel ther-
apies has seen a significant improvement in the median
survival of some groups of MM patients, the survival for
some subgroups of patients, particularly those with highly
proliferative disease, remains poor [7]. This highlights the
need to identify new genes and pathways that may be
involved in the pathophysiology of MM to aid in both
prognosis and the development of novel therapeutics.
The C57BL/KaLwRij (KaLwRij) mouse strain, a closely
related derivative of the C57BL/6 strain, is one of the
best-studied pre-clinical animal models of MM. The
KaLwRij strain is susceptible to developing benign
monoclonal gammopathy and, in a small proportion of
mice, MM at >2 years of age [8, 9]. Additionally, KaL-
wRij mice exhibit an inherent ability to support the
growth of exogenous malignant plasma cells. The intra-
venous injection of murine myeloma cell lines, such as
the KaLwRij-derived lines 5T33MM, 5T2MM and
5TGM1, into KaLwRij mice results in a myeloma-like
disease that closely resembles human MM [10–14]. The
mechanisms responsible for this susceptibility to the de-
velopment of myeloma in this strain of mice remain
largely unknown. Importantly, we [15, 16] and others
[17] have previously utilised this model to identify key
genes whose expression may play a role in the develop-
ment of MM disease in these mice.
We have previously identified pituitary tumour trans-
forming gene 1 (Pttg1) (also known as securin, EAP1
and TUTR1) as a gene that displays significantly in-
creased expression in KaLwRij mice compared with
C57BL/6 controls [15]. Notably, PTTG1 is over-expressed
in a vast array of malignancies including pituitary [18, 19],
colorectal [20], thyroid [21] and lung [22] cancer, and high
levels of PTTG1 are commonly associated with an en-
hanced proliferative capacity, increased tumour grade and
high invasive potential [23]. PTTG1 is a key regulator of
sister chromatid segregation during mitosis and, addition-
ally, is involved in DNA damage repair [23]. An increase
in PTTG1 expression has previously been described in up
to 63 % of MM patients [24, 25]; however, the role played
by PTTG1 in MM disease development has not been de-
termined. In the present study, we confirm up-regulation
of PTTG1 in MM plasma cells from a subset of MM pa-
tients compared with both MGUS and healthy controls
and show that elevated PTTG1 expression is associated
with an increase in cell cycle-related gene expression and
is associated with poor survival. Furthermore, knockdown
of Pttg1 decreases cellular proliferation in vitro and re-
duces myeloma tumour burden in vivo in the KaLwRij
model of MM. Collectively, these data support a role for
PTTG1 in promoting MM disease pathogenesis, likely
through cell cycle- and proliferation-related pathways.
Results
PTTG1 is over-expressed in the C57BL/KaLwRij mouse
model of myeloma
In order to identify genes that may play a role in the
development of myeloma, we previously compared the
transcriptome of the bone/BM of KaLwRij mice to that
of the genetically related C57BL/6 strain using micro-
array [15]. Using this approach, we identified Pttg1 as a
gene with significantly increased expression (2.9-fold;
p = 0.00037, LIMMA) within the bone/BM of KaLwRij
mice compared with C57BL/6 controls [15]. Quantita-
tive real-time PCR (qRT-PCR) was subsequently used
to assess the relative messenger ribonucleic acid
(mRNA) expression levels of Pttg1 in a range of tissues
derived from the C57BL/6 and KaLwRij mice (n = 3/
group). As seen in Fig. 1a, Pttg1 mRNA levels were sig-
nificantly increased in the bone, BM, peripheral blood
and spleen of KaLwRij mice, when compared with
those of C57BL/6 controls (p < 0.05, t test). Although
an increase in Pttg1 expression was also noted in the
thymus, this did not reach significance (p = 0.11, t test).
Furthermore, there was a significant increase in Pttg1
expression in CD138+ plasma cells derived from KaL-
wRij mice compared with those from C57BL/6 controls
(Fig. 1b; p = 0.045, t test). Together, these data confirm
that Pttg1 expression levels are up-regulated in the bone,
haematopoietic tissues and plasma cells of KaLwRij mice.
PTTG1 is over-expressed in MM patients and is associated
with poor survival
To examine whether MM patients display increased
PTTG1 expression, we performed in silico analyses in
three independent publically available microarray data-
sets (E-GEOD-6477; E-GEOD-16122; E-MTAB-363)
comparing the gene expression profiles of CD138+-iso-
lated plasma cells from newly diagnosed MGUS and
MM patients and normal controls. In E-GEOD-6477
and E-MTAB-363, PTTG1 expression was significantly
increased in the MM patient cohort compared with the
normal controls (p < 0.05) and MGUS patients (p < 0.05;
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Fig. 2a, b). In E-GEOD-16122, PTTG1 expression was
significantly increased in MM patients compared with
MGUS patients (p < 0.05; Fig. 2c). Approximately 38–70 %
(38.4 % [28/73], E-GEOD-6477; 70.3 % [109/155], E-
MTAB-363; 68.4 % [66/133], E-GEOD-16122) of MM pa-
tients expressed PTTG1 at levels higher than the normal
range (mean + 2SD of the normal cohort expression). We
subsequently isolated CD138+ plasma cells from diag-
nostic MM patient BM (n = 11) using CD138-MACS,
total RNA was isolated and PTTG1 mRNA expression
examined by qRT-PCR. Four of the 11 patients (36.4 %)
were found to express PTTG1 in the purified plasma
cells (Additional file 1: Figure S1). Using dual-colour
immunohistochemistry, we also confirmed PTTG1 pro-
tein expression within CD138+ plasma cells in BM tre-
phines from two PTTG1-expressing MM patients
(Fig. 2d). Consistent with previous reports [24, 26],
PTTG1 protein was predominantly cytoplasmic.
Collectively, these data suggest that over-expression
of PTTG1 is a feature of MM disease in approximately
36–70 % of MM patients. In order to determine
whether the increased expression of PTTG1 in MM
patients was related to patient survival, newly diagnosed
MM patients enrolled in the total therapy 2 (TT2) trial,
from publically available microarray dataset GSE4581,
were stratified based on PTTG1 expression levels. The
quartile with the highest PTTG1 expression was classified
as PTTG1 high (n = 71 patients), while the remaining
patients (n = 214) were classified as PTTG1 low. Subse-
quent analysis of overall survival identified a signifi-
cantly poorer survival in the PTTG1 high group
(hazard ratio 2.49; 95 % CI 1.28 to 4.86; p = 0.0075; log-
rank [Mantel-Cox] test; Fig. 2e).
When MM patients in dataset GSE4581 were parti-
tioned into gene expression profiling-defined sub-
groups (UAMS classifications) [4], elevated PTTG1 was
found to be associated with specific disease subtypes
(Fig. 2f ). Specifically, PTTG1 expression was elevated
in the PR subgroup, characterised by expression of
proliferation-related genes, when compared with the
subgroups characterised by chromosomal transloca-
tions involving cyclin D1 and D3 (CD1 and CD2), MAF
Fig. 1 Pttg1 expression is increased in haematopoietic tissues of C57BL/KaLwRij mice. a Bone, bone marrow (BM), peripheral blood (PB), spleen
and thymus and combined popliteal, inguinal and axillary lymph node tissues were isolated from C57BL/6 and C57BL/KaLwRij mice (n = 3/group)
and total RNA extracted. Pttg1 mRNA expression was determined by qRT-PCR analysis. *p < 0.05, t test. b CD138+ plasma cells (PC) were isolated
from the BM of C57BL/6 and C57BL/KaLwRij mice (n = 3/group). Pttg1 mRNA was significantly increased in KaLwRij-derived plasma cells compared
with C57BL/6 controls. Graphs depict mean + SEM; *p < 0.05, t test
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(MF) or MMSET (MS), by hyperdiploidy (HY) or by a
decreased prevalence of lytic bone disease (LB) (Fig. 2f ).
Additionally, significantly elevated PTTG1 was ob-
served in the HY group, when compared with the CD2,
LB, MF and MS subgroups.
PTTG1 expression in MM patients is associated with an
increase in expression of cell cycle-associated genes
As elevated PTTG1 expression was shown to be associ-
ated with poor outcomes in MM patients, we next com-
pared MM plasma cell gene expression between PTTG1
Fig. 2 PTTG1 is over-expressed in MM patients. In silico analysis was performed on publically available gene expression datasets from CD138+
plasma cells isolated by MACS from MM (n= 73) and MGUS (n= 22) patients and healthy controls (n= 15) (E-GEOD-6477) (a), MM (n = 155) and MGUS
(n= 5) patients and healthy controls (n = 5) (E-MTAB-363) (b) and MM (n= 133) and MGUS (n= 11) patients and healthy controls (n= 5) (E-GEOD-16122)
(c). Box and whiskers plots show the median and interquartile ranges for each cohort. *p < 0.05; **** p< 0.0001; Kruskal-Wallis test with Dunn’s multiple
comparison tests. d Representative image of a BM trephine section from an MM patient stained with anti-CD138 (red) and anti-PTTG1 (green), showing
plasma cell-specific protein expression of PTTG1. A negative (no primary antibody) control is shown. e Kaplan-Meier plot of PTTG1 high patients (quartile
4; n= 71) vs PTTG1 low patients (quartiles 1–3; n= 214) (TT2 patients from GSE4581). f MM patients from GSE4581 (n= 414) were stratified into subgroups
based on the UAMS criteria; namely, patients characterised by increased proliferation-related genes (PR), chromosomal translocations involving cyclin D1
and cyclin D3 (CD1 and CD2), MAF (MF) or MMSET (MS), as well as patients exhibiting hyperdiploidy (HY) and decreased prevalence of lytic
bone disease (LB) [4]. The expression of PTTG1 was analysed in each subset. Box and whiskers plots show the median and interquartile ranges
for each cohort; ^p < 0.0001 relative to CD1, CD2, MF, MS, HY and LB; #p < 0.01 relative to CD2, MF, MS, LB; Kruskal-Wallis test with Dunn’s
multiple comparison tests
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high and PTTG1 low MM patients in four independent
microarray datasets. Twenty-nine genes were found to
be significantly down-regulated, and 1459 genes signifi-
cantly up-regulated (excluding PTTG1) in at least one
dataset (Fisher’s p value <0.05). Of these, 155 genes were
significantly up-regulated, and no genes were down-
regulated, in all four datasets. Of the 119 of these genes
that were classified in DAVID, there was an enrichment
for cell cycle-related genes, with 82/119 (68.9 %) being
genes associated with mitosis. Genes up-regulated by
more than twofold, all with a strong (p < 0.0001) positive
correlation (Spearman) with PTTG1 expression, included
key cell cycle regulators (eg. CCNB1, CCNB2, CDK1,
CKS2), genes associated with DNA replication (eg.
MCM2, GINS1, RRM2), response to DNA damage (eg.
CHEK1, PBK), mitotic spindle and microtubule organisa-
tion (eg. AURKA, NEK1, PRC1), chromosome segregation
during mitosis (eg. CENPA, CENPH, PENPK, BIRC5) and
ubiquitin ligase activity and protein catabolism (eg.
UBE2C, CDC20, MAD2L1, DTL) (Table 1; Fig. 3). Other
non-cell cycle genes associated with high PTTG1 include
DEPDC1 and the histone demethylase EZH2.
Pttg1 knockdown in 5TGM1 cells inhibits cell proliferation
in vitro
Consistent with the elevated expression of Pttg1 in
KaLwRij-derived plasma cells and the KaLwRij mouse
tumour origin of the 5TGM1 cell line [27, 28], 5TGM1
cells express high levels of Pttg1 (data not shown).
Using lentiviral transduction, we stably introduced a
short hairpin ribonucleic acid (shRNA) within an
mCherry-tagged vector to specifically knockdown Pttg1
in luciferase-expressing 5TGM1 cells. Pttg1 expression
levels, as assessed by qRT-PCR (Fig. 4a) and Western
blot (Fig. 4b), were reduced by 70 % in the knockdown
cell line (denoted 5TGM1-PTTG-kd) when compared
with a scrambled shRNA control line (5TGM1-SCRAM).
These cell lines were used for subsequent in vivo and in
vitro experiments.
As high PTTG1 expression in MM patients correlates
with increased expression of cell cycle- and proliferation-
associated genes, we next examined whether Pttg1 may
play a role in modulating cell cycle progression and prolif-
eration in murine myeloma plasma cells. After 3 days of
culture, cell number, as determined by water-soluble tetra-
zolium salt (WST-1) assay, was significantly decreased by
75 % in the 5TGM1-PTTG-kd cells when compared with
the 5TGM1-SCRAM controls (Fig. 4c, p < 0.01, two-way
ANOVA with Sidak’s multiple comparison tests). Further-
more, the proliferative capacity of the 5TGM1-PTTG-kd
line in vitro was decreased by 83 % compared with the
5TGM1-SCRAM control, as determined by bromodeox-
yuridine (BrdU) incorporation over 2 h (Fig. 4d, p = 0.018,
t test). However, there was no effect of Pttg1 knockdown
on cell cycle distribution, as determined by propidium
iodide (PI) staining (Fig. 4e, p = 0.998, two-way ANOVA).
Furthermore, cell viability, as assessed by trypan blue
exclusion, was not affected by Pttg1 knockdown (data not
shown). Taken together, these results suggest that elevated
expression of Pttg1 in the malignant 5TGM1 cells may be
associated with increased cell proliferation.
Pttg1 knockdown reduces the expression of proliferation-
related genes in the 5TGM1 mouse myeloma cell line
In order to elucidate a potential mechanism through
which loss of Pttg1 inhibits proliferation, we examined
the expression of a selection of proliferation-related
genes identified in the human patient datasets (see
Table 1) in the 5TGM1-PTTG1-kd cell line compared
with the 5TGM1-SCRAM control. Our findings show that
expression of genes encoding the cell cycle regulator
Ccnb1 (p = 0.0039, t test) and the kinetochore-associated
protein Birc5 (p = 0.0008, t test) were decreased by 52 and
48 %, respectively, in the PTTG1-kd cells, compared with
the scramble control cells (Fig. 5). In contrast, expression
of genes encoding the cell cycle regulator Cdk1 and the
deoxyribonucleotide synthesis enzyme Rrm2 were not
affected by Pttg1 knockdown (p = 0.2391, t test). Add-
itionally, expression of Depdc1, which has previously
been implicated in MM [29], was decreased by 38 %
(p = 0.0055, t test) in the PTTG1-kd cells.
Pttg1 knockdown in 5TGM1 cells reduces tumour burden
in vivo
To ascertain whether the observed decrease in prolifer-
ation in the 5TGM1-PTTG-kd cells corresponded with
reduced tumour growth in vivo, the 5TGM1-PTTG-kd
and 5TGM1-SCRAM cell lines were injected i.v. into
C57BL/KaLwRij mice and tumour burden was moni-
tored at weekly intervals by bioluminescent imaging.
As seen in Fig. 6, tumour burden was decreased by
83 % in the Pttg1 knockdown group compared with the
control group at 4 weeks (p < 0.0001, two-way ANOVA
with Sidak’s post-test), suggesting that high basal ex-
pression of Pttg1 in 5TGM1 cells is important for in
vivo tumour growth.
Discussion
Over-expression of PTTG1 has previously been linked
to neoplastic transformation in a wide range of cell types
[23, 30–32]. Increased expression of PTTG1 has been
extensively studied in pituitary adenomas, as well as a
range of other endocrine cancers (reviewed by [33]). By
comparison, little is known about the role PTTG1 may
play in haematological malignancies. Early studies dem-
onstrated that PTTG1 was highly expressed in approxi-
mately 70 % of patients with leukaemia, lymphoma or
other myelodysplastic diseases but not in healthy donors
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Table 1 Gene significantly upregulated more than twofold in PTTG1 high MM patients
Probeset IDa Gene symbol Fisher’s p valueb Fold changec [mean (95 % CI)]
Regulation Of cell cycle
213226_at CCNA2 2.20 × 10−31 2.32 (1.84–2.80)
214710_s_at CCNB1 2.18 × 10−40 4.07 (2.61–5.53)
202705_at CCNB2 1.98 × 10−41 3.54 (1.93–5.14)
203213_at CDK1 9.11 × 10−37 3.91 (2.44–5.39)
1555758_a_at CDKN3 1.63 × 10−40 2.90 (1.68–4.13)
204170_s_at CKS2 2.02 × 10−35 2.88 (2.69–3.07)
218350_s_at GMNN 1.03 × 10−32 2.32 (1.71–2.93)
204825_at MELK 5.20 × 10−35 2.67 (1.88–3.47)
DNA replication
206102_at GINS1 6.74 × 10−29 2.99 (1.91–4.07)
202107_s_at MCM2 1.04 × 10−33 2.33 (1.79–2.87)
201930_at MCM6 5.41 × 10−20 2.03 (1.32–2.74)
201202_at PCNA 1.74 × 10−22 2.36 (1.81–2.91)
204127_at RFC3 3.82 × 10−17 2.12 (1.27–2.97)
209773_s_at RRM2 2.80 × 10−36 4.15 (2.38–5.92)
1554696_s_at TYMS 7.15 × 10−41 2.47 (0.95–4.00)
Response to DNA damage
205394_at CHEK1 1.33 × 10−36 2.74 (1.88–3.61)
213007_at FANCI 2.04 × 10−24 2.25 (1.04–3.47)
202503_s_at KIAA0101 1.34 × 10−38 3.59 (2.23–4.96)
223700_at MND1 9.45 × 10−41 2.03 (1.44–2.92)
219148_at PBK 3.18 × 10−38 3.62 (1.60–5.64)
205909_at POLE2 5.33 × 10−25 2.08 (1.49–2.67)
204146_at RAD51AP1 2.74 × 10−26 2.41 (1.56–3.26)
219258_at TIPIN 2.66 × 10−33 2.06 (1.70–2.41)
204033_at TRIP13 4.71 × 10−38 2.45 (1.87–3.04)
Mitotic spindle and microtubule organisation
208079_s_at AURKA 4.49 × 10−35 2.74 (2.22–3.26)
204162_at NDC80 1.96 × 10−32 3.23 (1.85–4.62)
204641_at NEK2 1.24 × 10−29 2.84 (1.65–4.03)
218039_at NUSAP1 9.20 × 10−37 3.47 (1.29–5.66)
218009_s_at PRC1 4.37 × 10−31 2.54 (1.69–3.39)
222077_s_at RACGAP1 5.24 × 10−31 3.01 (1.90–4.13)
209891_at SPC25 3.04 × 10−40 2.84 (2.62–3.06)
200783_s_at STMN1 1.27 × 10−34 2.33 (1.73–2.94)
204822_at TTK 1.30 × 10−34 2.66 (1.03–4.28)
204026_s_at ZWINT 4.49 × 10−29 3.09 (1.01–5.17)
Sister chromatid segregation
202095_s_at BIRC5 8.63 × 10−38 2.60 (1.94–3.26)
204962_s_at CENPA 7.33 × 10−38 2.97 (2.14–3.81)
231772_x_at CENPH 2.98 × 10−32 2.12 (1.76–2.47)
222848_at CENPK 5.40 × 10−31 2.90 (1.86–3.94)
219555_s_at CENPN 1.53 × 10−33 2.06 (1.45–2.67)
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Table 1 Gene significantly upregulated more than twofold in PTTG1 high MM patients (Continued)
226936_at CENPW 2.43 × 10−39 2.40 (1.39–3.41)
218663_at NCAPG 2.21 × 10−34 2.61 (1.44–3.79)
213599_at OIP5 6.22 × 10−41 2.99 (2.39–3.59)
Ubiquitin ligase activity
202870_s_at CDC20 1.02 × 10−36 2.43 (2.28–2.58)
222680_s_at DTL 4.43 × 10−29 2.88 (1.22–4.55)
203362_s_at MAD2L1 1.01 × 10−32 3.07 (1.92–4.23)
202954_at UBE2C 2.48 × 10−37 2.20 (1.15–3.24)
223229_at UBE2T 4.11 × 10−30 2.30 (0.82–3.78)
Chromatin modification
203358_s_at EZH2 1.21 × 10−24 2.41 (1.63–3.20)
227212_s_at PHF19 1.18 × 10−29 2.38 (1.59–3.17)
Other
222958_s_at DEPDC1 2.47 × 10−25 2.32 (1.31–3.32)
226980_at DEPDC1B 2.52 × 10−33 2.37 (2.00–2.74)
225834_at FAM72A/FAM72B/FAM72C/FAM72D 1.10 × 10−29 3.31 (1.01–5.62)
228069_at MTFR2 1.36 × 10−31 2.07 (1.62–2.53)
235113_at PPIL5 3.17 × 10−27 2.08 (1.53–2.63)
229551_x_at ZNF367 1.30 × 10−20 2.20 (1.48–2.93)
aGenes are shown for which statistically significant differences were observed in all of the four datasets analysed. Data is shown for the Affymetrix probeset with
the lowest p value for each gene
bFisher’s method was used to combine the p values across the four datasets
cMean fold change observed for PTTG1 high vs PTTG1 low patients across the four datasets
Fig. 3 PTTG1 expression strongly correlates with expression of cell proliferation-related genes in MM patients. PTTG1 expression in 328 newly
diagnosed MM patients (E-GEOD-19784) plotted against expression of cell cycle-related genes CDK1 (a), CCNB1 (b), CCNB2 (c), BIRC5 (d), RRM2
(e) and the non-cell cycle gene DEPCD1 (f). r and p values are shown for Pearson correlation analyses
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[26, 34]. More recently, high PTTG1 protein expression
has been observed in 63 % of MM patients [24, 25];
however, the biological and prognostic significance of
PTTG1 over-expression was not investigated in these
studies. In the current study, we show a significant
increase in PTTG1 expression in human MM patients,
with approximately 36–70 % of patients showing
increased expression of PTTG1 above that seen in
healthy controls, findings which were subsequently con-
firmed by analysis of our own MM patient specimens.
Importantly, increased PTTG1 expression was associated
with poor overall survival, suggesting that high PTTG1
expression may be implicated in MM disease severity
and poor patient outcome. Additionally, our analyses
show that PTTG1 is upregulated in MM patients, but
not in the asymptomatic precursor MGUS, suggesting
an association with disease progression.
Chromosomal rearrangements and duplications are
early events in the development of myeloma with the
presence of genomic instability being associated with
poor prognosis [35]. In this study, elevated PTTG1 was
specifically observed in a subgroup of MM patients
displaying a hyperdiploid phenotype (HY group). This is
consistent with the role of PTTG1 in regulating sister
chromatid separation during mitosis [36, 37] as dysregu-
lation of this key function commonly leads to genomic
instability [38–42]. Over-expression of PTTG1 promotes
dysregulated chromosome segregation resulting in aneu-
ploidy in human cancer cell lines [40, 41, 43]. The chromo-
somal instability induced by PTTG1 over-expression has
been proposed as a mechanism whereby PTTG1 drives
malignant transformation [44]. Interestingly, gene expres-
sion profiling studies have shown that the presence of
chromosomal instability in newly diagnosed myeloma pa-
tients is associated with a gene expression profile that
includes upregulation of PTTG1 [35]. These data suggest
that expression of PTTG1 in MM patients may contribute
to the development of chromosome duplications charac-
teristic of the HY group.
In addition to its association with hyperdiploidy, we
found a significant increase in PTTG1 expression in
subset of patients with a proliferation-related gene ex-
pression profile (PR group), which is associated with
high-risk disease and poor prognosis [4]. Elevated
Fig. 4 Pttg1 knockdown reduces 5TGM1 proliferation in vitro. a A 70 % knockdown of Pttg1 mRNA was confirmed in 5TGM1-PTTG-kd cells compared
with 5TGM1-SCRAM controls by qRT-PCR. b Reduced protein expression of Pttg1 was confirmed by Western blot. c Cells were seeded at 1 × 105 cells/
mL in a 96-well plate, and cell numbers over 3 days were quantitated by WST-1 assay, read at 450 nm. d Cells were seeded at 4 × 105 cells/mL in a 96-well
plate, BrdU substrate was added and BrdU incorporation was quantitated after 2 h by ELISA, measured by absorbance at 370 nm. *p< 0.05, t test. e Cells
were seeded at 4 × 105 cells/mL in a six-well plate and cultured for 24 h, and cell cycle distribution was assessed following PI staining. Representative FACS
plots (PI histograms) are shown. Graphs depict mean + SEM of three independent experiments
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PTTG1 has previously been identified as part of a gene
signature that is associated with increased proliferative
index and is an independent predictor of poor progno-
sis in newly diagnosed MM patients [45]. The increase
in PTTG1 in MM patients with highly proliferative dis-
ease is consistent with data from other systems which
show that increased expression of PTTG1 correlates
with high levels of cellular proliferation [46–48]. While,
in the short term, over-expression of PTTG1 prevents
exit from mitosis, leading to cell cycle arrest and in-
creased cell death [49, 50], sustained; stable over-
expression of PTTG1 generally leads to enhanced
Fig. 5 Pttg1 knockdown results in deregulation of proliferation-related genes in 5TGM1 cells. Expression of Ccnb1, Birc5, Cdk1, Rrm2 and Depcd1
was quantitated in 5TGM1-PTTG-kd cells compared with 5TGM1-SCRAM controls by qRT-PCR. Graphs depict mean + SD of triplicates from a single
experiment. *p < 0.05, t test
Fig 6 Pttg1 knockdown reduces tumour growth in vivo. a Total tumour burden was measured at 2-, 3- and 4-weeks post-tumour cell inoculation
using bioluminescence imaging techniques. A significant reduction in total tumour burden was observed in the Pttg kd group (n = 15) compared
with SCRAM controls (n = 10); ****p < 0.001, two-way ANOVA with Sidak’s post-test. b Representative bioluminescent images of mice injected with
5TGM1-SCRAM control (left) and 5TGM1-PTTG-kd (right) cells at 4-weeks post-tumour cell inoculation are shown
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cellular proliferation [32, 51, 52]. Notably, our Pttg1
knockdown studies in the KaLwRij-derived 5TGM1
myeloma plasma cell line resulted in a reduction in cel-
lular proliferation in vitro, as well as decreased tumour
development in vivo. This is consistent with a number
of animal knockout and knockdown studies in a range
of different cell types, which show that reduction of
PTTG1 expression inhibits cell proliferation [52–59].
Taken together, these data are consistent with increased
expression of Pttg1 being a core requirement for the
growth of malignant plasma cells in some patients.
In support of the pro-proliferative role of PTTG1 in
myeloma, analysis of four independent MM patient
gene expression datasets revealed that the majority
(68.9 %) of genes significantly up-regulated in PTTG1
high patients had proliferation-related functions, specif-
ically cell cycle regulation, DNA replication, mitotic
spindle formation, chromosome segregation and DNA
damage pathways. These included 20 of the top 50
genes originally identified as being upregulated in the
PR subgroup [4]. Notable exclusions include the can-
cer/testis antigens MAGEA1, MAGEA3, MAGEA6,
GAGE1, GAGE2, GAGE4 and GAGE5, which were ori-
ginally identified as being strongly upregulated in the
PR subgroup [4] but are not upregulated in our PTTG1
high patients. This, combined with the strength of the as-
sociation between PTTG1 expression and the expression
of cell cycle-associated genes, suggests that the upregula-
tion of proliferation-related genes with high PTTG1 ex-
pression is not simply due to an increased representation
of PR patients in this group.
Indeed, we found that knockdown of Pttg1 was asso-
ciated with downregulation of cell cycle regulatory
genes in the 5TGM1 cell line, suggesting a potential
mechanism for the decreased proliferation observed in
these cells. Cell cycle genes CcnB1 (cyclin B1) and Birc5
(survivin), which were among the most highly up-
regulated genes identified in our patient analysis, were
down-regulated by approximately 50 % by Pttg1 knock-
down in the 5TGM1 cells. Both CCNB1 and BIRC5
have been identified as part of gene expression signa-
tures predictive of high-risk disease and poor prognosis
in MM patients in several studies [4, 5, 45, 60–63].
PTTG1, CCNB1 and BIRC5 expression are under tight
transcriptional control during cell cycle progression,
being switched on during G2/M phase [46, 49, 64, 65].
While this suggests that downregulation of Ccnb1 and
Birc5 expression following Pttg1 could be a consequence
of a decrease in G2/M phase cells, we saw no change in
cell cycle distribution in the PTTG1-kd cells to support
this. Cyclin B1, an essential regulator of cell cycle transi-
tion during mitosis, has previously been identified as a
PTTG1-regulated gene whose up-regulation is associated
with enhanced proliferation in keratinocytes [52]. BIRC5
is an inhibitor of apoptosis proteins (IAP) family member
which regulates microtubule dynamics and chromosomal
segregation during mitosis. Over-expression and knock-
down studies in human myeloma cell lines have impli-
cated BIRC5 in proliferation and protection of MM cells
from apoptosis [62, 64, 66]. Taken together, these data
suggest a potential role for cyclin B1 and BIRC5 in
PTTG1-mediated tumour growth.
In addition to its role as a securin during chromatid
segregation, PTTG1 can directly regulate gene expres-
sion. PTTG1 has been shown to physically interact with
p53, repressing its transcriptional activity [36]. Add-
itionally, p53 expression can be transcriptionally and
translationally repressed by transient over-expression of
PTTG1 [67]. Notably, some of the genes found to
strongly correlate with PTTG1 expression in this study,
including CDK1, CCNB1, CCNB2 and BIRC5 are known
to be inhibited downstream of p53 [68–70]; p53-mediated
regulation of gene expression down stream of PTTG1
could be a focus of future studies. However, we found no
correlation between PTTG1 and p53 expression in MM
patients in any of the datasets examined (data not shown),
suggesting that PTTG1 is unlikely to transcriptionally
downregulate p53 expression in plasma cells from MM
patients. Additionally, our data suggests that PTTG1 up-
regulation in MM patients is not a consequence of dele-
tion of the p53 locus 17p13, or associated TP53 mutations
[71], which is observed in approximately 10 % of patients
and is itself associated with poor prognosis [72–74].
In addition to cell cycle genes, we found that expres-
sion of DEPDC1 (Dishevelled, EGL-10, Pleckstrin do-
main containing 1) was significantly up-regulated in
PTTG1 high patients. Importantly, Pttg1 knockdown in
myeloma cells leads to a 40 % reduction in DEPDC1 ex-
pression. While the function of DEPDC1 is unknown,
its expression has been associated with poor prognosis
in lung cancer [75] and advanced disease in breast can-
cer [76]. Knockdown of DEPDC1 or inhibition using a
specific peptide results in decreased cell proliferation and
apoptosis in bladder cancer cell lines [77, 78]. In myeloma,
DEPDC1 expression has been associated with poor prog-
nosis [29]. In addition, shRNA-mediated DEPCD1 knock-
down in human myeloma cell lines was shown to
significantly inhibit cell proliferation and induce accumu-
lation in G2/M in TP53 wild-type cells and marked apop-
tosis in TP53 mutant cells [29]. These data suggest that
regulation of DEPDC1 expression may be a mechanism
whereby PTTG1 regulates cell proliferation in myeloma.
Although studies have identified a role for PTTG1 in
regulating epithelial-mesenchymal transition (EMT)
[79–81] and recent studies by Azab and colleagues [82]
have identified a role for the EMT processes in the dis-
semination and homing of MM plasma cells to the BM,
we showed no association between the expression of
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EMT-related genes and high PTTG1 expression in MM
patients. In addition, PTTG1 has previously been
shown to directly mediate pro-angiogenic pathways
through regulation of secreted factors VEGF and FGF-2
[19, 83, 84], which in turn are commonly expressed in
MM and associated with increased disease severity
[85–87]. However, our analyses did not identify an in-
crease in these, or other, secreted pro-angiogenic fac-
tors in the presence of increased PTTG1 expression in
MM patients. These data suggest that PTTG1 is un-
likely to function through EMT or angiogenic pathways
in modulating MM disease.
Conclusions
In summary, we have identified PTTG1 as a gene which
is over-expressed in the MM-susceptible KalwRij mouse
and in MM patients with hyperdiploidy or with hyper-
proliferative disease, suggesting a role in MM disease
development. Knockdown of Pttg1 significantly inhib-
ited the proliferation of myeloma cells in vitro, with an
associated decrease in the expression of mitosis-related
genes, and slowed tumour development in vivo. While
expression of PTTG1 has previously been noted in gene
expression signatures defining myeloma patients with
highly proliferative disease [4] and chromosomal in-
stability [35] and, by association, poor outcomes, this is
the first study to show that PTTG1 expression alone is
sufficient to identify a subset of patients with poor
overall survival. Collectively, our data suggest that the
poor prognosis associated with PTTG1 expression is
due to a hyperproliferative state in these patients,
which may result from the PTTG1-mediated upregula-
tion of key drivers of cell cycle progression.
Materials and methods
Mouse tissue and plasma cell isolation
C57BL/6 mice were obtained from the Animal Re-
sources Centre (Perth, Australia). C57BL/KaLwRij mice,
originally kindly provided by Prof. Andrew Spencer
(Monash University, Melbourne, Australia), were bred
and housed at the SA Pathology Animal Care Facility
(Adelaide, Australia). Tissues from C57BL/6 and C57BL/
KaLwRij mice were snap frozen in liquid nitrogen and
homogenised in TRIzol (Life Technologies, Carlsbad,
CA). Blood was obtained from mice by cardiac puncture,
collected in microfuge tubes containing 50 μL 0.5 M
EDTA and centrifuged for 10 min at 500g and the cell
pellet resuspended in TRIzol by vigorous vortexing.
Femora and tibiae from age- and sex-matched C57BL/6
and C57BL/KaLwRij mice were extracted and cleaned
thoroughly. A 21-gauge needle was inserted into the BM
cavity, and the BM was flushed with ice-cold PFE (PBS/
2 %FCS/2 mM EDTA). The resulting cell suspension
was subjected to Ficoll density gradient separation and
collected in 10 mL PFE, followed by centrifugation at
300g for 5 min at 4 °C. BM cells were immediately lysed
in TRIzol, or CD138+ plasma cells were isolated by
FACS. Briefly, cells were resuspended at 1 × 107 cells/mL
in PFE and blocked with 110 μg/mL murine gamma
globulin (Jackson Laboratories, Bar Harbor, ME) for
30 min at 4 °C. Cells were stained for 30 min at 4 °C
protected from light with rat anti-mouse CD138 (R &
D Systems, Minneapolis, MN) or an isotype control,
washed twice with PFE and stained with secondary goat
anti-rat IgG PE (Southern Biotech, Birmingham, AL)
for 30 min at 4 °C protected from light. Cells were
washed three times with PFE, followed by sorting for
CD138+ cells on a FACSAria II (BD Biosciences, San
Jose, CA). Total RNA was isolated from sorted cells
using an RNAqueous Micro kit (Life Technologies).
Microarray analysis
For comparison of PTTG1 expression in CD138+ BM
plasma cells, isolated by CD138-MACS, from newly diag-
nosed MM or MGUS patients or normal controls, three
independent datasets were used: E-GEOD-6477 (normal,
n = 5; MGUS, n = 11; MM, n = 133 [61]), E-GEOD-16122
(normal, n = 15; MGUS, n = 22; MM, n = 73 [88]) and E-
MTAB-363 (normal, n = 5; MGUS, n = 5; MM, n = 156
[89]). Analysis of PTTG1 expression in different gene
expression-defined (UAMS) patient subsets was con-
ducted in GSE4581 (n = 414) [4]. Analysis of patient sur-
vival in PTTG1 high and PTTG1 low newly diagnosed
MM patients was carried out using GSE4581 analysing pa-
tients included in the total therapy 2 (TT2) trial (n = 256).
Four independent datasets were used for analysis of gene
expression in PTTG1 high (quartile 4) and PTTG1 low
(quartiles 1–3) patient subsets in CD138-selected BM
plasma cells from newly diagnosed MM patients: E-
GEOD-19784 (n = 328) [90], E-GEOD-26863 (n = 304)
[91], E-MTAB-317 (n = 226) [45] and E-MTAB-363 (n =
156). E-MTAB-363, E-GEOD-26863, E-MTAB-317 and
GSE4581 were conducted on Affymetrix GeneChip Human
Genome U133 plus 2.0 arrays; E-GEOD-6477 and E-
GEOD-16122 were conducted on Affymetrix GeneChip
Human Genome U133A arrays. For all datasets except
GSE4581, raw microarray data (CEL files) were down-
loaded from ArrayExpress (EMBL-EBI) and were normal-
ised by RMA using the bioconductor package (affy) [92]
and R (version 3.03) and log2 transformed. One patient in
E-MTAB-363 (V0681) failed quality control (normalised
unscaled standard error [NUSE] >1.05) and was excluded,
and the remaining 165 files were re-normalised. For
GSE4581, MAS5-normalised data were downloaded from
the Gene Expression Omnibus (GEO) and were log2 nor-
malised prior to analysis. GO annotation (http://www.ge-
neontology.org) and DAVID [93, 94] were used to classify
genes by related function.
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MM patient samples
BM trephines and aspirates were collected, with in-
formed consent, from patients with MM at the time of
diagnosis and prior to initiation of therapy. This study
was approved by the Royal Adelaide Hospital Human
Research Ethics Committee (application # RAH 030206
and 131133).
CD138+ plasma cell isolation from MM patients
CD138+ plasma cells were isolated from diagnostic MM
patient BM samples using CD138 microbeads (Miltenyi
Biotech, Auburn, CA) as previously described [15].
Briefly, cryopreserved human BM samples were thawed
into 10 mL DMEM (high glucose) with 15 % FCS and
DNase I (80 U/mL). Samples were centrifuged at 300g
for 10 min and supernatant removed. The cell pellet
was resuspended in MACS buffer (2 mM EDTA, 0.5 %
deionised BSA in PBS) and CD138 microbeads added,
followed by incubation on ice for 15 min. Cell-bead conju-
gates were washed in 1 mL MACS buffer and centrifuged
at 300g for 10 min. Cells were resuspended in MACS buf-
fer, applied to a pre-rinsed MS column and washed three
times with MACS buffer and eluted in 1 mL. Subsequent
FACS analysis confirmed >85 % CD138+ following MACS.
Total RNA was isolated using an All Prep DNA/RNA
Micro Kit (Qiagen, Valencia, CA).
Dual colour staining BM trephines
Paraffin-embedded BM trephine sections were mounted
on silicane-coated slides and dried. Endogenous peroxid-
ase was blocked with 0.5 % H2O2 in methanol at room
temperature for 30 min, followed by blocking with 3 %
normal horse serum (NHS) for 30 min. Slides were incu-
bated with anti-PTTG1 antibody (diluted 1:50; DCS-280;
Abcam) at room temperature overnight. Slides were
washed twice in PBS and incubated with biotinylated
anti-mouse IgG (Vector Laboratories, Burlingame, CA)
diluted 1:250 for 30 min at room temperature, washed
in PBS and incubated with streptavidin Alexa Fluor 488
(diluted 1:500; Life Technologies) diluted 1:500 for 1 h
at room temperature. Slides were re-blocked with 3 %
NHS for 30 min and incubated with mouse anti-human
CD138 (diluted 1:40; MI15, Dako, Denmark) overnight.
Slides were washed twice with PBS followed by incubation
for 1 h at room temperature with anti-mouse Alexa Fluor
594 (diluted 1:500, Life Technologies) and mounted in
aqueous mounting solution. Images were taken on a Zeiss
LSM 700 confocal system (Zeiss, Oberkocken, Germany)
at ×40 magnification.
Cell lines
The murine myeloma plasma cell line 5TGM1 was
kindly provided by Ass. Prof. Claire Edwards (University
of Oxford, Oxford, UK), and was maintained in Iscove’s
modified Dulbecco’s medium (Sigma) with 20 % FCS.
Unless otherwise specified, all culture medium was sup-
plemented with 2 mM L-glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin, 10 mM HEPES buffer (Life
Technologies) and 1 mM sodium pyruvate.
Generation of stable PTTG1 knockdown lines
To generate stable knockdown cell lines, an RNA duplex
targeting murine Pttg1 (GGGAAATTGCAGGTTTCAA
CG) was cloned into the pFIV-H1-mCherry vector. A
scrambled sequence was used as a control. pFIV-H1-
mCherry was created by excising the GFP cassette from
pFIV-H1-GFP (System Biosciences, Mountain View, CA)
using XbaI and SalI and replacing it with the mCherry
cassette from pMSCV-mCherry. Following lentiviral in-
fection of 5TGM1-luc cells (expressing a dual GFP and
luciferase reporter construct [16, 96, 97]), single-cell
clones were generated from the top 10 % GFP- and
mCherry-expressing cells using preparative cell sorting
and the automatic cell deposition unit on a Beckman
Coulter Epics Altra HyperSort, using Expo MultiComp
Software version 1.2B (Beckman Coulter, Miami, FL).
Clonal 5TGM1-PTTG-kd and 5TGM1-SCRAM lines
were used for subsequent in vitro and in vivo assays.
Real-time PCR
Total RNA was isolated using TRIzol (Life Technologies)
as per the standard protocol (unless otherwise specified).
For mouse and human CD138+ plasma cells, RNA was
reverse transcribed using Sensiscript (Qiagen). For all
other tissues and cell lines, RNA (1 μg) was reverse tran-
scribed with Superscript III (Life Technologies) as per
the manufacturer’s protocol. Real-time PCR was con-
ducted on the Corbett Rotorgene using the following
primers: human β-actin (F: 5'-TTGCTGACAGGATGCA-
GAAG-3' and R: 5'-AAGGGTGTAAAACGCAGCTC-3'),
human PTTG1 (F: 5'-CGGCCTCAGATGAATGCGGCT-
3' and R: 5'-TTGATTGAAGGTCCAGACCCCAGC-3'),
mouse Gapdh (F: 5'- ACCCAGAAGACTGTGGATGG-3'
and R: 5'-CAGTGAGCTTCCCGTTCAG-3'), mouse β-
actin (F: 5'-TTG CTGACAGGATGCAGAAG-3' and R:
5'-CAGTGAGCTTCCCGTTCA-3'), mouse Pttg1 (F: 5'-
GCTCCTGATGATGCCTACCC-3' and R: 5'-CGCCATT-
CAAGGGGAGAAGT-3'), mouse Ccnb1 (F: 5'-GATGAT
GGGGCTGACCCAAA-3' and R: 5'-ACATGGTCTCCT
GAAGCAGC-3'), mouse Cdk1 (F: 5'-GTCCGTCGTAA
CCTGTTGAG-3' and R: 5'-TGACTATATTTGGATGTC
GAAG-3') [98], mouse Rrm2 (F: 5'-GATTTAGCCAAG
AAGTTCAAGTTACAG-3' and R: 5'-TCACACAAGG-
CATAGTTTCAATAGC-3') [99], mouse Birc5 (F: 5'-GAA
CCCGATGACAACCCGAT–3' and R: 5'-TGGTCTCCTT
TGCAATTTTGTTCT-3') and mouse Depcd1 (F: 5'-AGC
TGCAGTGGAGAAACATCT-3' and R: 5'-TGGTCTCCTT
TGCAATTTTGTTCT-3'). Gene expression was represented
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relative to β-actin or Gapdh expression, calculated using
the 2-ΔCT method.
Western blot analysis
Cells were lysed in lysis buffer (1 % NP-40, 20 mM
HEPES, 150 mM NaCl, 10 % glycerol, 2 mM Na3VO4,
10 mM Na4P2O7, 2 mM NaF and Complete EDTA-free
Protease Inhibitor Cocktail (Roche, Mannheim,
Germany)). Total lysate (10 μg) was loaded on an 11 %
acrylamide gel and subjected to SDS-PAGE. Proteins
were transferred to PVDF membrane overnight. Mem-
brane was incubated for 1 h in blocking buffer (Tris-
buffered saline containing 0.1 % Tween20 and 2.5 %
ECL Blocking Agent (GE Healthcare, Little Chalfont,
UK)) and for 2 h at RT with mouse monoclonal anti-
PTTG1 antibody (DCS-280; Abcam; Cambridge, MA)
diluted 1:1000 in blocking buffer, followed by alkaline
phosphate-conjugated anti-mouse IgG (Millipore, Billerica,
MA) diluted 1:4000 in blocking buffer for 1 h at RT. Pro-
teins were visualised using ECL detection reagent (GE
Healthcare) on a Typhoon FLA 7000 IP2 (GE Healthcare).
Proliferation assays
For WST-1 assays, 5TGM1 cells (PTTG-kd or SCRAM
controls) were seeded at 1 × 105 cells/well in triplicate in
96-well plates and were incubated at 37 °C with 5 %
CO2. At 24-h intervals, WST-1 reagent (Roche) was
added to the cells and incubated for 2 h prior to reading
absorbance at 450 nm.
For BrdU assays, 5TGM1 cells were seeded at 4 × 105
cells/well in triplicate in a 96-well plate. BrdU (Roche)
was immediately added to the cells and incubated for
2 h at 37 °C with 5 % CO2. BrdU incorporation was
measured using a BrdU Cell Proliferation ELISA kit
(Roche) as per manufacturer’s protocol and absorbance
measured at 370 nm.
For cell cycle analysis, cells were seeded at 4 × 105
cells/well in a six-well plate and incubated for 24 h at
37 °C with 5 % CO2. Cells were fixed in ice-cold 70 %
(v/v) ethanol, washed twice in PBS and stained with pro-
pidium iodide (PI; 40 μg/mL; Sigma) containing 20 μg/
mL RNase A (Qiagen) for 30 min prior to analysis on a
Gallios flow cytometer (Beckman Coulter). Cell cycle
distribution was analysed using FCS Express version 4.
Animals
Ethical approval for this study was obtained from the SA
Pathology/Adelaide Health Service Animal Ethics Com-
mittee (application # 136/10). C57BL/KaLwRij mice at
6–8 weeks of age were injected with 5 × 105 luciferase-
expressing 5TGM1-luc cells (5TGM1-SCRAM or
5TGM1-PTTG-kd) in 100-μl sterile PBS via the tail vein.
At weekly intervals, mice were administered luciferin
(150 mg/kg) i.p. and imaged using the Xenogen IVIS 100
bioluminescence imaging system (Caliper Life Sciences,
Hopkinton, MA) until termination of the experiment at
day 28, prior to the development of lethal disease (hind
limb paralysis) [16, 96]. Total tumour burden was mea-
sured as total flux (photons/second) for each animal using
Living Image software (PerkinElmer, Waltham, MA), as
described previously [15, 16, 97, 100–103].
Statistical analyses
Statistical analysis was performed using GraphPad
Prism version 6.03 for Windows (GraphPad Software,
San Diego, CA). Variance between patient groups was
assessed using Kruskal-Wallis tests with Dunn’s mul-
tiple comparison tests. In each of the E-GEOD-19784,
E-GEOD-26863, E-MTAB-317 and E-MTAB-363 data-
sets, gene expression was compared in PTTG1 high
and PTTG1 low patients, using t tests with Bonferroni’s
correction for multiple testing and p values from the
four datasets were combined using Fisher’s method.
Survival curves were compared using the log-rank (Man-
tel-Cox) test with hazard ratios calculated using the
Mantel-Haenszel calculation. In vivo data, WST-1 assays
and cell cycle distribution were analysed by two-way
ANOVA with Sidak’s multiple comparison tests. qRT-PCR
data and BrdU incorporation were compared between
groups using unpaired two-tailed t tests. A p value of 0.05
was considered statistically significant. Unless otherwise
described, all plots depict mean + SEM of three independ-
ent experiments.
Additional file
Additional file 1: Figure S1. PTTG1 expression is upregulated in MM
PC. PTTG1 expression was quantitated in CD138-selected BM PC from
newly diagnosed MM patients (n = 11) using qRT-PCR. Graph shows
mean + SD of triplicates from a single experiment.
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